Thiazolidinedione analogs for treatment of NAFLD and metabolic diseases

• Main Authors: FARMER BRIAN K, COTTLE-DAVIDSON BETH ANNE, COLKA GERARD R, COTTLE GERD, DITTRICH HOWARD C
• Format: Patent
• Language: Chinese; English
• Published: 01.11.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Provided herein are thiazolidinedione analogs for use in the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation mediated diseases and conditions. In addition, the present invention provides non-invasive methods and systems for assessing the risk of a subject having NASH. In addition, provided herein are non-invasive methods and systems for evaluating whether treatment of NASH is effective. 本文提供了用于治疗非酒精性脂肪肝病(NAFLD)、非酒精性脂肪性肝炎(NASH)、糖尿病和其他代谢性炎症介导的疾病和病症的噻唑烷二酮类似物。此外，本发明提供了用于评估对象患有NASH的风险的非侵入性方法和系统。此外，本文提供了用于评价NASH的治疗是否有效的非侵入性方法和系统。